SGLT2 Inhibitors and Bone Health: Fracture Risk Considerations

Imagine you’re managing your type 2 diabetes with a medication that protects your heart and kidneys. It sounds like a win-win, right? But then you hear whispers about bone fractures. Suddenly, that protective shield feels like it might be cracking your bones instead of saving them. This is the exact dilemma many patients and doctors face when discussing SGLT2 inhibitors, a class of drugs including canagliflozin, empagliflozin, and dapagliflozin.

The short answer? The fear has been largely overstated for most drugs in this class. However, one specific medication carries a warning that still matters today. If you are on these meds or considering them, you need to know which ones are safe for your skeleton and which ones require extra caution.

The Origin of the Fear: Why Do We Worry About Bones?

To understand where we stand in 2026, we have to look back at 2015. That’s when the FDA issued its first warnings about increased fracture risk linked specifically to canagliflozin (brand name Invokana). This wasn’t just a rumor; it came from hard data in the CANVAS trial. Patients taking this drug had more fractures than those on a placebo. The concern was real enough that the label changed, adding a warning about fractures occurring as early as 12 weeks after starting treatment.

So, why would a blood sugar drug hurt your bones? Scientists have proposed several mechanisms:

• Weight Loss Effects: SGLT2 inhibitors cause weight loss (typically 2-4 kg). While losing weight is generally good, rapid loss can sometimes trigger bone resorption markers. However, research suggests weight loss explains only about 3% of the variance in these bone markers.
• Hormonal Shifts: Some studies showed that women on high-dose canagliflozin experienced a drop in estradiol levels by 9.2%. Since estrogen protects bone density, this drop could theoretically weaken bones.
• Falls Risk: These drugs can cause a slight drop in blood pressure when standing up (postural hypotension), affecting 0.4-1.0% of patients. If you feel dizzy and fall, you’re more likely to break a bone, regardless of bone strength.
• Phosphate Handling: The drugs change how your kidneys handle phosphate, which might trigger hormonal responses that affect bone turnover.

But here is the crucial part: not all SGLT2 inhibitors act the same way. Treating them as a single group with one risk profile is a mistake.

Not All SGLT2 Inhibitors Are Equal

This is where the story gets interesting. While canagliflozin raised red flags, other drugs in the same class told a different story. Let’s look at the big trials:

In the CANVAS trial, canagliflozin resulted in 15.4 fractures per 1,000 person-years compared to 11.9 for placebo. That’s a noticeable jump. But look at empagliflozin and dapagliflozin. Their massive cardiovascular outcome trials showed no such spike. In fact, a major meta-analysis published in January 2023 in HIV/NATAP combined data from 27 randomized controlled trials involving over 20,000 participants. The result? A pooled relative risk of 1.02, which essentially means no correlation between SGLT2 inhibitors as a whole and higher fracture risk.

Even more reassuring, a 2023 study in JAMA Network Open found that SGLT2 inhibitors actually had similar or lower fracture risks compared to other common diabetes drugs like GLP-1 receptor agonists. The absolute risk difference was -0.32 fractures per 100 person-years. So, if you were worried these drugs were worse for your bones than your current regimen, the data says otherwise.

What Do the Guidelines Say in 2026?

Medical guidelines evolve as evidence accumulates. By 2023, the American Diabetes Association (ADA) updated its Standards of Care to reflect this nuance. They now state that "SGLT2 inhibitors as a class do not appear to increase fracture risk," while acknowledging that canagliflozin specifically has shown modest increases in some studies.

The FDA maintains its specific warning for canagliflozin but has not required additional label changes for other agents since 2018. The European Medicines Agency (EMA) takes a slightly broader view, requiring class-wide warnings about potential bone effects without singling out specific drugs, but US regulators remain precise.

Real-world usage reflects this shift. According to IQVIA data, canagliflozin prescriptions in the U.S. declined by 22% between 2017 and 2022. Meanwhile, empagliflozin and dapagliflozin prescriptions surged by 38% and 42%, respectively. Doctors are voting with their pens, choosing the options with cleaner safety profiles regarding bone health.

Who Should Be Cautious?

While the general population can breathe easier, certain groups still need to tread carefully. You fall into the high-risk category if:

• You have established osteoporosis (a T-score ≤ -2.5).
• You have a history of previous fractures.
• You are elderly and prone to falls.
• You are prescribed the 300 mg dose of canagliflozin.

Dr. Sarah Chen, an endocrinologist at Mayo Clinic, noted in a 2023 webinar that she observes approximately 3-4 fractures per 1,000 patient-years with canagliflozin versus 2-3 with other SGLT2 inhibitors among elderly patients with multiple comorbidities. It’s a small difference in absolute numbers, but for someone already fragile, every bit counts.

If you are in this high-risk group, the American College of Endocrinology recommends getting a dual-energy X-ray absorptiometry (DXA) scan before starting canagliflozin. If your T-score is below -2.0, doctors often consider alternative therapies. The ADA’s Fracture Risk Assessment Tool even adds 0.5 points to your FRAX score specifically for canagliflozin use, but not for other agents in the class.

Practical Steps for Patients and Doctors

How do you navigate this in real life? Here is what leading experts suggest:

1. Know Your Drug: Ask your doctor exactly which SGLT2 inhibitor you are taking. If it’s empagliflozin or dapagliflozin, rest easy. If it’s canagliflozin, ask if switching makes sense given your bone health.
2. Fall Prevention: Since dizziness can lead to falls, rise slowly from sitting or lying down. Stay hydrated, especially in hot weather, to minimize blood pressure drops.
3. Bone Density Monitoring: If you are on long-term therapy and have other risk factors (like smoking, low calcium intake, or family history), discuss periodic DXA scans with your provider. Dr. Felicia Cosman of the National Osteoporosis Foundation recommends monitoring for any patient on long-term SGLT2 inhibitors with additional risk factors.
4. Calcium and Vitamin D: Ensure you are meeting baseline requirements for bone health. This isn’t unique to SGLT2 inhibitors, but it becomes more critical if you are concerned about fractures.

A 2022 survey of endocrinologists revealed that 68% modify their prescribing based on fracture risk, with 82% avoiding canagliflozin in patients with osteoporosis. Only 34% expressed similar caution with dapagliflozin. This shows that experienced clinicians are already making these distinctions routine.

The Bottom Line

The narrative around SGLT2 inhibitors and bone health has shifted dramatically. What started as a broad alarm bell has narrowed into a targeted caution for one specific drug. For the vast majority of people with type 2 diabetes, the cardiovascular and renal benefits of empagliflozin and dapagliflozin far outweigh any theoretical bone risks. Even for canagliflozin, the risk is manageable with proper assessment and monitoring.

Don’t let outdated fears stop you from using medications that protect your heart and kidneys. Instead, have an informed conversation with your healthcare provider. Bring up your bone health history, ask about your specific drug’s profile, and decide together on the safest path forward. Your bones matter, but so does your overall metabolic health.